Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 1, 2018-01 ,pp. : e69-e69

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized, double‐blind, placebo‐controlled, phase II clinical trial to investigate the efficacy and safety of oral DA‐1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 31, Iss. 3, 2015-03 ,pp. : 295-306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and Safety of Etanercept in Patients With the Enthesitis‐Related Arthritis Category of Juvenile Idiopathic Arthritis: Results From a Phase III Randomized, Double‐Blind Study

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 8, 2015-05 ,pp. : 2240-2249

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 66, Iss. 12, 2014-12 ,pp. : 3255-3264

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1562-1574

John Wiley & Sons Inc

Access to resources Recommend Favorite